[{"Assets_0_Q2_USD":220179000.0,"EarningsPerShareBasic_1_Q2_USD":0.3,"EarningsPerShareBasic_2_Q2_USD":1.8,"EarningsPerShareDiluted_1_Q2_USD":0.28,"EarningsPerShareDiluted_2_Q2_USD":1.7,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":25112000.0,"NetIncomeLoss_1_Q2_USD":4503000.0,"NetIncomeLoss_2_Q2_USD":27427000.0,"StockholdersEquity_0_Q2_USD":165362000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":15219777.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":15238729.0,"Ticker":"EGRX","CIK":"827871","name":"EAGLE PHARMACEUTICALS, INC.","OfficialName":"Eagle Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"635235963.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170809"}]